LEXINGTON, Mass., April 28, 2020 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of agents designed to activate immune response to
cancers, will release its first quarter 2020 financial results
before the market opens on Thursday, May 7,
2020. Agenus executives will host a conference call and
webcast at 8:30 a.m. ET the same day
to discuss the results and provide a business update.
To access the live call, dial 1-844-492-3727 (U.S.) or
1-412-317-5118 (International) and ask to be joined into the Agenus
call. The call will also be webcast and will be accessible from the
Company's website at
http://investor.agenusbio.com/presentation-webcasts or with this
link https://www.webcaster4.com/Webcast/Page/1556/34323.
A replay will be available on the Company's website
approximately one hour after the call and will remain available
until July 7, 2020.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the
discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and twitter.
Contact
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original
content:http://www.prnewswire.com/news-releases/agenus-to-report-first-quarter-2020-financial-results-on-may-7-2020-and-host-conference-call-and-webcast-301048534.html
SOURCE Agenus Inc.